Dihydromyricetin alleviates inflammatory bowel disease associated intestinal fibrosis by inducing autophagy through the PI3K/AKT/mTOR signaling pathway.

MLA

Wang, XiaoChun, et al. “Dihydromyricetin Alleviates Inflammatory Bowel Disease Associated Intestinal Fibrosis by Inducing Autophagy through the PI3K/AKT/MTOR Signaling Pathway.” Naunyn-Schmiedeberg’s Archives of Pharmacology, vol. 397, no. 6, June 2024, pp. 4183–94. EBSCOhost, https://doi.org/10.1007/s00210-023-02856-0.

APA

Wang, X., Li, X., Ma, X., Zhang, L., Han, T., & Zhang, D. (2024). Dihydromyricetin alleviates inflammatory bowel disease associated intestinal fibrosis by inducing autophagy through the PI3K/AKT/mTOR signaling pathway. Naunyn-Schmiedeberg’s Archives of Pharmacology, 397(6), 4183–4194. https://doi.org/10.1007/s00210-023-02856-0

Chicago

Wang, XiaoChun, XiaoLi Li, XueNi Ma, LuDan Zhang, TiYun Han, and DeKui Zhang. 2024. “Dihydromyricetin Alleviates Inflammatory Bowel Disease Associated Intestinal Fibrosis by Inducing Autophagy through the PI3K/AKT/MTOR Signaling Pathway.” Naunyn-Schmiedeberg’s Archives of Pharmacology 397 (6): 4183–94. doi:10.1007/s00210-023-02856-0.